Actively Recruiting
Study of Oral Rifaximin to Treat Active Microscopic Colitis with Collagenous or Lymphocytic Types
Led by Eugene F Yen, MD · Updated on 2021-04-15
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of oral rifaximin therapy for treating patients with active microscopic colitis, including both collagenous and lymphocytic types. This open-label Phase 2 trial aims to study the effectiveness and safety of rifaximin in reducing symptoms and improving tissue changes seen in this condition. The study focuses on patients experiencing frequent watery or loose stools related to microscopic colitis. Participants will take 550 mg of rifaximin three times daily for four weeks. There is one treatment group receiving this open-label medication. The studys primary goals are to assess clinical remission, defined as fewer than three stools per day and less than one watery stool daily during the previous week, and to evaluate histologic response regarding disease severity. A secondary goal includes assessing changes in the Microscopic Colitis Disease Activity Index MCDAI. During the study, researchers will monitor stool frequency and consistency, perform biopsies to check tissue response, and track disease activity scores over six weeks. Participants will be involved in clinical assessments and follow-up visits to measure these outcomes. Safety and symptom remission will be evaluated throughout the study period to understand rifaximins potential role in managing microscopic colitis.
CONDITIONS
Brief Title
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
Research Team
D
Daniel Amusin, BS
I
Iris Chiou, BA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here